

SUPPLEMENTARY MATERIAL

Table S1. Demographic and clinical characteristics of studied patients.

	ACO	NO ACO	P value
No. of subjects (%)	32 (14.7)	186 (85.3)	
Demographic characteristics			
Individual characteristics			
Female sex, N (%)	22 (68.75)	130 (69.89)	NS
Age, years, mean (SD)	53.19 (8.935)	45.37 (12.01)	0.0005
Caucasian ethnicity, N (%)	32 (14.68)	176 (94.62)	NS
Body mass index (BMI), mean (SD)	28.25 (5.590)	27.66 (5.824)	NS
Obesity, N (%)	11 (34.38)	48 (25.81)	NS
Residency, urban area, N (%)	19 (59.38)	144 (77.42)	0.04
Comorbidities, N (%)			
Atopy	27 (84.38)	136 (73.12)	NS
Allergic rhinitis	17 (53.13)	96 (51.61)	NS
Bronchiectasis	5 (15.63)	16 (8.60)	NS
CRSwNP	14 (43.75)	53 (28.49)	NS (0.09)
CRSsNP	3 (9.38)	13 (6.99)	NS
Obstructive sleep apnoea syndrome (OSAS)	3 (9.38)	11 (5.91)	NS
Smoking habit, N (%)			
Never smoker	0 (0.0)	124 (66.67)	<0.0001
Current smoker	14 (43.75)	11 (5.91)	<0.0001
Ex-smoker	21 (65.63)	49 (26.34)	<0.0001
Education level, N (%)			
Higher education	24 (75)	136 (73.12)	NS
Primary education	5 (15.63)	43 (23.12)	NS
No studies	2 (6.25)	3 (1.61)	NS
Clinical characteristics			
Treatment, N (%)			
ICS/LABA	26 (81.25)	141 (75.81)	NS
Long-term OCS	5 (15.63)	8 (4.30)	0.02
Biologicals	4 (12.50)	36 (19.35)	NS
Asthma severity, N (%)			
Intermittent	0 (0)	13 (6.99)	0.02
Mild persistent	4 (12.50)	35 (18.82)	NS
Moderate persistent	11 (34.38)	69 (37.10)	NS
Severe persistent	17 (53.13)	63 (33.87)	0.04
Exacerbations, N (%)			
Patients with asthma exacerbation during previous year	17 (53.13)	71 (38.17)	NS
Exacerbations over the previous year, mean (SD)	3.353 (1.869)	2.634 (2.674)	0.02
Severe asthma exacerbation during previous year	7 (21.88)	26 (13.98)	NS
Patient with emergency room (ER) visits	11 (34.38)	48 (25.81)	NS
≥5 ER visits	1 (3.13)	3 (1.61)	NS
Emergency room (ER) visits, mean (SD)	0.91 (1.42)	0.66 (1.56)	NS
ICU admission	3 (9.38)	14 (7.53)	NS
Asthma control in ACT N (%)			
Completely controlled (ACT ≥20)	3 (9.38)	50 (26.8)	0.04
Not-controlled (ACT ≤ 19)	29 (90.62)	136 (73.11)	<0.05

ACT=asthma control test; CRSwNP=chronic rhinosinusitis with nasal polyposis; CRSsNP=chronic rhinosinusitis without nasal polyposis; CI=confidence interval; ICU=intensive care unit.

Table S2. Functional and inflammatory characteristics of studied patients.

	ACO	NO ACO	P value
No. of subjects (%)	32 (14.7)	186 (85.3)	
Respiratory function tests and biomarkers			
Spirometry, mean (SD)			
FEV1 (L)	2.06 (0.81)	2.85 (0.83)	<0.0001
FVC (L)	2.28 (0.86)	3.01 (0.84)	<0.0001
FEV1/FVC (%)	61.12 (8.52)	85.27 (12.15)	<0.0001
Positive spirometry bronchodilator test, N (%)	16 (50)	34 (18.28)	0.0004
Spirometry with GLI, mean (SD)			
FEV1 (z-score)	-2.14 (1.2)	-0.56 (1.2)	<0.0001
FVC (z-score)	0.87 (6.36)	-0.30 (1.2)	NS
FEV1/FVC(z-score)	-2.79 (0.70)	-0.50 (1.01)	<0.0001
FEV1(LLN)	2.01 (0.64)	2.35 (0.61)	0.04
FVC (LLN)	2.59 (0.81)	2.91 (0.75)	0.05
FEV1/FVC (LLN)	0.68 (0.02)	0.69 (0.02)	0.01
Cellular sputum profile, N (%)			
Eosinophilic	2 (50.0%)	26 (42.6)	NS
Mixed	0 (0.0)	6 (9.8)	NS
Neutrophilic	1 (25)	7 (11.5)	NS
Paucigranulocytic	1 (25)	21 (34.4)	NS

FEV₁=forced expiratory volume in one second; FVC=forced vital capacity.